10-Q Filing

IMMIX BIOPHARMA, INC. CIK: 1873835 Q3 2023

Filing Information

Form Type	10-Q
Accession Number	`0001493152-23-040182`
Period End Date	20230930
Filing Date	20231113
Fiscal Year	2023
Fiscal Period	Q3
XBRL Instance	form10-q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 68 Income Statement 88 Cash Flow Statement 60 Stockholders Equity 50

Balance Sheet 68 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$13.44M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$19.58M	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Tax receivable	`IncomeTaxReceivable`	$652.48K	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Tax receivable	`IncomeTaxReceivable`	$255.71K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$2.10M	USD	Point-in-time
Common stock par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.21M	USD	Point-in-time
Common stock par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$14.90M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$22.33M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	13.96M	shares	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$103.19K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$6.72K	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	19.68M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	19.61M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	13.89M	shares	Point-in-time
Equipment, net	`PropertyPlantAndEquipmentNet`	$40.08K	USD	Point-in-time
Equipment, net	`PropertyPlantAndEquipmentNet`	$3.56K	USD	Point-in-time
Total assets	`Assets`	$22.47M	USD	Point-in-time
Treasury stock, shares	`TreasuryStockCommonShares`	72,363.00	shares	Point-in-time
Total assets	`Assets`	$14.91M	USD	Point-in-time
Treasury stock, shares	`TreasuryStockCommonShares`	72,363.00	shares	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.27M	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$2.83M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.83M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.27M	USD	Point-in-time
Funds held for subsidiary private offering	`FundsHeldForSubsidiaryPrivateOfferingNonCurrent`	$475.00K	USD	Point-in-time
Funds held for subsidiary private offering	`FundsHeldForSubsidiaryPrivateOfferingNonCurrent`	-	USD	Point-in-time
Total liabilities	`Liabilities`	$1.75M	USD	Point-in-time
Total liabilities	`Liabilities`	$2.83M	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $0.0001 par value; 200,000,000 shares authorized; 19,681,091 shares issued and 19,608,728 shares outstanding at September 30, 2023 and 13,964,485 shares issued and 13,892,122 shares outstanding at December 31, 2022	`CommonStockValue`	$1.40K	USD	Point-in-time
Common stock, $0.0001 par value; 200,000,000 shares authorized; 19,681,091 shares issued and 19,608,728 shares outstanding at September 30, 2023 and 13,964,485 shares issued and 13,892,122 shares outstanding at December 31, 2022	`CommonStockValue`	$1.97K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$51.16M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$68.15M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$46.73K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$87.02K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-48.32M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-37.99M	USD	Point-in-time
Treasury stock at cost, 72,363 shares as of September 30, 2023 and December 31, 2022	`TreasuryStockValue`	$99.96K	USD	Point-in-time
Treasury stock at cost, 72,363 shares as of September 30, 2023 and December 31, 2022	`TreasuryStockValue`	$99.96K	USD	Point-in-time
Total Immix Biopharma, Inc. stockholders equity	`StockholdersEquity`	$13.16M	USD	Point-in-time
Total Immix Biopharma, Inc. stockholders equity	`StockholdersEquity`	$19.77M	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	-	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$-124.67K	USD	Point-in-time
Total stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$16.75M	USD	Point-in-time
Total stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$17.99M	USD	Point-in-time
Total stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$19.65M	USD	Point-in-time
Total stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.74M	USD	Point-in-time
Total stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$13.17M	USD	Point-in-time
Total stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$13.16M	USD	Point-in-time
Total stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.11M	USD	Point-in-time
Total stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$19.65M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$14.91M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$22.47M	USD	Point-in-time

Income Statement 88 line items

Line Item	Tag	Value	Unit	Period
General and administrative expenses	`GeneralAndAdministrativeExpense`	$2.42M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$5.13M	USD	3 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$837.44K	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$2.49M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$2.11M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$5.63M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$1.93M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$695.94K	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$4.52M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$10.77M	USD	3 Qtrs
Total operating expenses	`OperatingExpenses`	$4.42M	USD	3 Qtrs
Total operating expenses	`OperatingExpenses`	$1.53M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-10.77M	USD	3 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-4.42M	USD	3 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-1.53M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-4.52M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	-	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$186.69K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	-	USD	3 Qtrs
Interest income	`InvestmentIncomeInterest`	$343.43K	USD	3 Qtrs
Interest expense	`InterestExpense`	-	USD	1 Quarter
Interest expense	`InterestExpense`	-	USD	3 Qtrs
Interest expense	`InterestExpense`	-	USD	1 Quarter
Interest expense	`InterestExpense`	$497.00	USD	3 Qtrs
Total other income (expense), net	`NonoperatingIncomeExpense`	$186.69K	USD	1 Quarter
Total other income (expense), net	`NonoperatingIncomeExpense`	-	USD	1 Quarter
Total other income (expense), net	`NonoperatingIncomeExpense`	$-497.00	USD	3 Qtrs
Total other income (expense), net	`NonoperatingIncomeExpense`	$343.43K	USD	3 Qtrs
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-4.34M	USD	1 Quarter
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-1.53M	USD	1 Quarter
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-4.42M	USD	3 Qtrs
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-10.42M	USD	3 Qtrs
Provision for income taxes	`IncomeTaxExpenseBenefit`	$18.33K	USD	3 Qtrs
Provision for income taxes	`IncomeTaxExpenseBenefit`	$6.81K	USD	1 Quarter
Provision for income taxes	`IncomeTaxExpenseBenefit`	$1.67K	USD	1 Quarter
Provision for income taxes	`IncomeTaxExpenseBenefit`	$5.01K	USD	3 Qtrs
Net loss	`ProfitLoss`	$-10.44M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-4.43M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-1.56M	USD	1 Quarter
Net loss	`ProfitLoss`	$-2.50M	USD	1 Quarter
Net loss	`ProfitLoss`	$-4.34M	USD	1 Quarter
Net loss	`ProfitLoss`	$-3.60M	USD	1 Quarter
Net loss	`ProfitLoss`	$-1.54M	USD	1 Quarter
Net loss	`ProfitLoss`	$-1.33M	USD	1 Quarter
Net loss attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	-	USD	3 Qtrs
Net loss attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-103.61K	USD	3 Qtrs
Net loss attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-63.25K	USD	1 Quarter
Net loss attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	-	USD	1 Quarter
Net loss attributable to Immix Biopharma, Inc. common stockholders	`NetIncomeLoss`	$-10.34M	USD	3 Qtrs
Net loss attributable to Immix Biopharma, Inc. common stockholders	`NetIncomeLoss`	$-4.43M	USD	3 Qtrs
Net loss attributable to Immix Biopharma, Inc. common stockholders	`NetIncomeLoss`	$-1.54M	USD	1 Quarter
Net loss attributable to Immix Biopharma, Inc. common stockholders	`NetIncomeLoss`	$-4.28M	USD	1 Quarter
Foreign currency translation	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-40.29K	USD	3 Qtrs
Foreign currency translation	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-40.39K	USD	1 Quarter
Foreign currency translation	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-34.15K	USD	1 Quarter
Foreign currency translation	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-63.35K	USD	3 Qtrs
Total other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-40.29K	USD	3 Qtrs
Total other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-40.39K	USD	1 Quarter
Total other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-63.35K	USD	3 Qtrs
Total other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-34.15K	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-10.38M	USD	3 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-4.49M	USD	3 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-1.58M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-4.31M	USD	1 Quarter
Less: comprehensive loss attributable to non-controlling interests	`OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest`	-	USD	1 Quarter
Less: comprehensive loss attributable to non-controlling interests	`OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest`	-	USD	1 Quarter
Less: comprehensive loss attributable to non-controlling interests	`OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest`	-	USD	3 Qtrs
Less: comprehensive loss attributable to non-controlling interests	`OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest`	-	USD	3 Qtrs
Comprehensive loss attributable to Immix Biopharma, Inc. common stockholders	`OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest`	$-4.49M	USD	3 Qtrs
Comprehensive loss attributable to Immix Biopharma, Inc. common stockholders	`OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest`	$-4.31M	USD	1 Quarter
Comprehensive loss attributable to Immix Biopharma, Inc. common stockholders	`OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest`	$-1.58M	USD	1 Quarter
Comprehensive loss attributable to Immix Biopharma, Inc. common stockholders	`OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest`	$-10.38M	USD	3 Qtrs
Loss per common share - basic	`EarningsPerShareBasic`	$-0.65	USD	3 Qtrs
Loss per common share - basic	`EarningsPerShareBasic`	$-0.23	USD	1 Quarter
Loss per common share - basic	`EarningsPerShareBasic`	$-0.32	USD	3 Qtrs
Loss per common share - basic	`EarningsPerShareBasic`	$-0.11	USD	1 Quarter
Loss per common share - diluted	`EarningsPerShareDiluted`	$-0.23	USD	1 Quarter
Loss per common share - diluted	`EarningsPerShareDiluted`	$-0.11	USD	1 Quarter
Loss per common share - diluted	`EarningsPerShareDiluted`	$-0.65	USD	3 Qtrs
Loss per common share - diluted	`EarningsPerShareDiluted`	$-0.32	USD	3 Qtrs
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	13.92M	shares	1 Quarter
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	13.88M	shares	3 Qtrs
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	15.86M	shares	3 Qtrs
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	18.58M	shares	1 Quarter
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	15.86M	shares	3 Qtrs
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	18.58M	shares	1 Quarter
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	13.88M	shares	3 Qtrs
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	13.92M	shares	1 Quarter

Cash Flow Statement 60 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-10.44M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-4.43M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-1.56M	USD	1 Quarter
Net loss	`ProfitLoss`	$-2.50M	USD	1 Quarter
Net loss	`ProfitLoss`	$-4.34M	USD	1 Quarter
Net loss	`ProfitLoss`	$-3.60M	USD	1 Quarter
Net loss	`ProfitLoss`	$-1.54M	USD	1 Quarter
Net loss	`ProfitLoss`	$-1.33M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$1.51M	USD	3 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$393.98K	USD	3 Qtrs
Depreciation	`Depreciation`	$1.57K	USD	3 Qtrs
Depreciation	`Depreciation`	$2.39K	USD	3 Qtrs
Tax receivable	`IncreaseDecreaseInIncomeTaxesReceivable`	$175.44K	USD	3 Qtrs
Tax receivable	`IncreaseDecreaseInIncomeTaxesReceivable`	$427.48K	USD	3 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$923.91K	USD	3 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-207.54K	USD	3 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$1.58M	USD	3 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$506.94K	USD	3 Qtrs
Accrued interest	`IncreaseDecreaseInInterestPayableNet`	$-9.10K	USD	3 Qtrs
Accrued interest	`IncreaseDecreaseInInterestPayableNet`	-	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-8.69M	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-3.50M	USD	3 Qtrs
Purchase of equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$38.91K	USD	3 Qtrs
Purchase of equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	-	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-38.91K	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	-	USD	3 Qtrs
Payments of deferred offering costs	`PaymentOfFinancingAndStockIssuanceCosts`	$234.62K	USD	3 Qtrs
Payments of deferred offering costs	`PaymentOfFinancingAndStockIssuanceCosts`	-	USD	3 Qtrs
Proceeds from sale of common stock, net of offering costs	`ProceedsFromIssuanceOfCommonStock`	$14.94M	USD	3 Qtrs
Proceeds from sale of common stock, net of offering costs	`ProceedsFromIssuanceOfCommonStock`	$2.91M	USD	3 Qtrs
Proceeds from sale of Nexcella common stock	`ProceedsFromSaleOfNexcellaCommonStock`	-	USD	3 Qtrs
Proceeds from sale of Nexcella common stock	`ProceedsFromSaleOfNexcellaCommonStock`	$175.00K	USD	3 Qtrs
Payments on note payable	`RepaymentsOfNotesPayable`	-	USD	3 Qtrs
Payments on note payable	`RepaymentsOfNotesPayable`	$50.00K	USD	3 Qtrs
Repurchase of common stock	`PaymentsForRepurchaseOfCommonStock`	-	USD	3 Qtrs
Repurchase of common stock	`PaymentsForRepurchaseOfCommonStock`	$55.96K	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$2.81M	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$14.88M	USD	3 Qtrs
Effect of foreign currency on cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.80K	USD	3 Qtrs
Effect of foreign currency on cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-31.37K	USD	3 Qtrs
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$6.15M	USD	3 Qtrs
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-727.96K	USD	3 Qtrs
Cash and cash equivalents beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$13.44M	USD	Point-in-time
Cash and cash equivalents beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$17.64M	USD	Point-in-time
Cash and cash equivalents beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$19.58M	USD	Point-in-time
Cash and cash equivalents beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$16.92M	USD	Point-in-time
Cash and cash equivalents end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$13.44M	USD	Point-in-time
Cash and cash equivalents end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$17.64M	USD	Point-in-time
Cash and cash equivalents end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$19.58M	USD	Point-in-time
Cash and cash equivalents end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$16.92M	USD	Point-in-time
Interest paid	`InterestPaidNet`	-	USD	3 Qtrs
Interest paid	`InterestPaidNet`	$9.60K	USD	3 Qtrs
Income taxes paid	`IncomeTaxesPaidNet`	$18.33K	USD	3 Qtrs
Income taxes paid	`IncomeTaxesPaidNet`	-	USD	3 Qtrs
Nexcella shares issued for funds previously received	`NexcellaSharesIssuedForFundsPreviouslyReceived`	$475.00K	USD	3 Qtrs
Nexcella shares issued for funds previously received	`NexcellaSharesIssuedForFundsPreviouslyReceived`	-	USD	3 Qtrs
Deferred offering costs charged against proceeds from sale of common stock	`DeferredOfferingCostsChargedAgainstProceedsFromSaleOfCommonStock`	$131.43K	USD	3 Qtrs
Deferred offering costs charged against proceeds from sale of common stock	`DeferredOfferingCostsChargedAgainstProceedsFromSaleOfCommonStock`	-	USD	3 Qtrs
Common stock issued for cashless exercise of stock options	`CommonStockIssuedForCashlessExerciseOfStockOptions`	-	USD	3 Qtrs
Common stock issued for cashless exercise of stock options	`CommonStockIssuedForCashlessExerciseOfStockOptions`	$6.00	USD	3 Qtrs

Stockholders Equity 50 line items

Line Item	Tag	Value	Unit	Period
Beginning balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$16.75M	USD	Point-in-time
Beginning balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$17.99M	USD	Point-in-time
Beginning balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$19.65M	USD	Point-in-time
Beginning balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.74M	USD	Point-in-time
Beginning balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$13.17M	USD	Point-in-time
Beginning balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$13.16M	USD	Point-in-time
Beginning balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.11M	USD	Point-in-time
Beginning balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$19.65M	USD	Point-in-time
Shares issued under ATM facility for cash proceeds, net of offering costs	`StockIssuedDuringPeriodValueUnderAtmFacilityForCashProceedsNetOfOfferingCosts`	$4.58M	USD	1 Quarter
Shares issued under ATM facility for cash proceeds, net of offering costs	`StockIssuedDuringPeriodValueUnderAtmFacilityForCashProceedsNetOfOfferingCosts`	$185.28K	USD	1 Quarter
Shares issued under ATM facility for cash proceeds, net of offering costs	`StockIssuedDuringPeriodValueUnderAtmFacilityForCashProceedsNetOfOfferingCosts`	$101.32K	USD	1 Quarter
Nexcella shares issued for cash proceeds	`StockIssuedDuringPeriodValueOther`	$650.00K	USD	1 Quarter
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$65.07K	USD	1 Quarter
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$447.66K	USD	1 Quarter
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$737.33K	USD	1 Quarter
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$65.71K	USD	1 Quarter
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$329.92K	USD	1 Quarter
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$163.19K	USD	1 Quarter
Non-controlling interests in subsidiary	`NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance`	-	USD	1 Quarter
Non-controlling interests in subsidiary	`NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance`	-	USD	1 Quarter
Non-controlling interests in subsidiary	`NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance`	-	USD	1 Quarter
Net loss	`ProfitLoss`	$-10.44M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-4.43M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-1.56M	USD	1 Quarter
Net loss	`ProfitLoss`	$-2.50M	USD	1 Quarter
Net loss	`ProfitLoss`	$-4.34M	USD	1 Quarter
Net loss	`ProfitLoss`	$-3.60M	USD	1 Quarter
Net loss	`ProfitLoss`	$-1.54M	USD	1 Quarter
Net loss	`ProfitLoss`	$-1.33M	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax`	$-40.39K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax`	$-38.55K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax`	$15.59K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax`	$-4.47K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax`	$-1.67K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax`	$-34.15K	USD	1 Quarter
Shares and warrants issued under private placement for cash proceeds, net of offering costs	`StockIssuedDuringPeriodValueSharesAndWarrantIssuedUnderPrivatePlacement`	$9.93M	USD	1 Quarter
Shares issued for cash proceeds, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$2.91M	USD	1 Quarter
Shares issued for cashless exercise of option	`StockIssuedDuringPeriodValueStockOptionsExercised`	-	USD	1 Quarter
Shares issued for cashless exercise of option, shares	`StockIssuedDuringPeriodSharesStockOptionsExercised`	-	shares	3 Qtrs
Shares issued for services	`StockIssuedDuringPeriodValueIssuedForServices`	$50.00K	USD	1 Quarter
Shares issued for services	`StockIssuedDuringPeriodValueIssuedForServices`	$50.00K	USD	1 Quarter
Repurchase of common shares	`StockRepurchasedDuringPeriodValue`	$55.96K	USD	1 Quarter
Ending balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$16.75M	USD	Point-in-time
Ending balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$17.99M	USD	Point-in-time
Ending balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$19.65M	USD	Point-in-time
Ending balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.74M	USD	Point-in-time
Ending balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$13.17M	USD	Point-in-time
Ending balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$13.16M	USD	Point-in-time
Ending balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.11M	USD	Point-in-time
Ending balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$19.65M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.